The effectiveness and value of bempedoic acid and inclisiran for heterozygous familial hypercholesterolemia and secondary prevention of ASCVD: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
Open accessAbstract
Funding for this summary was contributed by Arnold Ventures, California Health Care Foundation, The Donaghue Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER's annual policy summit is supported by dues from AbbVie, Aetna, America's Health Insurance Plans, Anthem, Alnylam, AstraZeneca, Biogen, Blue Shield of CA, Boehringer-Ingelheim, Cambia Health Services, CVS, Editas, Evolve Pharmacy, Express Scripts, Genentech/Roche, GlaxoSmithKline, Harvard Pilgrim, Health Care Service Corporation, HealthFirst, Health Partners, Humana, Johnson & Johnson (Janssen), Kaiser Permanente, LEO Pharma, Mallinckrodt, Merck, Novartis, National Pharmaceutical Council, Pfizer, Premera, Prime Therapeutics, Regeneron, Sanofi, Spark Therapeutics, uniQure, and United Healthcare. Agboola, McKenna, and Pearson are employed by ICER. Lin and Kazi received funding from ICER for work on this report.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Inclisiran is cost-effective in patients with FH and has potential for significant cost savings in the post-MI population.
“Taken together, these papers suggest that inclisiran is a potent LDL-C lowering therapy that has the potential of significant cost savings in the post-MI population and is cost-effective in the population with FH.”
From Small Interfering RNA for LDL-Cholesterol Reduction (2026) · cites this paper as [23]
The cost-effectiveness discussion (page unavailable in our copy) says inclisiran had better modeled cost-effectiveness in the HeFH subgroup, but its assessment depends on an assumed price; it does not establish that inclisiran is cost-effective for all patients with FH. The paper evaluates a recent acute-coronary-syndrome subgroup but does not report significant cost savings in a post-MI population. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591 · see citing works
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550 · see citing works
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185 · see citing works
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182776f83 · Cited by 2,411 · see citing works
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J. A., Richardson, T., Jaros, M., Wijngaard, P. L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912387 · Cited by 1,665 · see citing works
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.013 · Cited by 1,560 · see citing works
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Raal, F. J., Kallend, D., Ray, K. K., Turner, T., Koenig, W., Wright, R. S., Wijngaard, P. L. J., Curcio, D., Jaros, M. J., Leiter, L. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913805 · Cited by 818 · see citing works
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
Ray, K. K., Bays, H. E., Catapano, A. L., Lalwani, N. D., Bloedon, L. T., Sterling, L. R., Robinson, P. L., & Ballantyne, C. M. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1803917 · Cited by 807 · see citing works
Goldberg, A. C., Leiter, L. A., Stroes, E. S. G., Baum, S. J., Hanselman, J. C., Bloedon, L. T., Lalwani, N. D., Patel, P. M., Zhao, X., & Duell, P. B. (2019) · JAMA · doi:10.1001/jama.2019.16585 · Cited by 481 · see citing works
Lloyd-Jones, D. M., Morris, P. B., Ballantyne, C. M., Birtcher, K. K., Daly, D. D., DePalma, S. M., Minissian, M. B., Orringer, C. E., & Smith, S. C. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.519 · Cited by 459 · see citing works
Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance
Laufs, U., Banach, M., Mancini, G. B. J., Gaudet, D., Bloedon, L. T., Sterling, L. R., Kelly, S., & Stroes, E. S. G. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011662 · Cited by 432 · see citing works
Ballantyne, C. M., Banach, M., Mancini, G. B. J., Lepor, N. E., Hanselman, J. C., Zhao, X., & Leiter, L. A. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.002 · Cited by 422 · see citing works
Ballantyne, C. M., Laufs, U., Ray, K. K., Leiter, L. A., Bays, H. E., Goldberg, A. C., Stroes, E. S., MacDougall, D., Zhao, X., & Catapano, A. L. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319864671 · Cited by 358 · see citing works
Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia
de Isla, L. P., Rodrigo Alonso, K., Watts, G. F., Mata, N., Cerezo, A. S., Muñiz-Grijalvo, O., Fuentes, F. J., Díaz-Díaz, J. L., de Andrés, R., Zambón, D., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.01.008 · Cited by 241 · see citing works
Mortality in the United States, 2022
Kochanek, K. D., Murphy, S. L., Xu, J., & Arias, E. (2023) · doi:10.15620/cdc:135850 · Cited by 210 · see citing works
Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction
Singh, A., Gupta, A., Collins, B., Qamar, A., Monda, K. L., Biery, D. W., López, J. A. G., de Ferranti, S. D., Plutzky, J., Cannon, C. P., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.02.059 · Cited by 108 · see citing works
Amrock, S. M., Duell, P. B., Knickelbine, T., Martin, S. S., O'Brien, E. C., Watson, K. E., Mitri, J., Kindt, I., Shrader, P. J., Baum, S. J., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.10.006 · Cited by 97 · see citing works
Zafrir, B., Shapira, C., Lavie, G., Halon, D. A., & Flugelman, M. Y. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.08.010 · Cited by 10 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Wilkinson, M. J., Lepor, N. E., & Michos, E. D. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.028892 · Cited by 69 · see citing works
Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
Bardolia, C., Amin, N. S., & Turgeon, J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.789931 · Cited by 69 · see citing works
Abushanab, D., Al‐Badriyeh, D., Marquina, C., Bailey, C., Jaam, M. J., Liew, D., & Ademi, Z. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101211 · Cited by 15 · see citing works
McQueen, R. B., Baum, S. J., Louie, M. J., Sasiela, W. J., Bilitou, A., Shah, H., Nash, B., Gillard, K. K., & Ray, K. K. (2022) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-022-00552-7 · Cited by 11 · see citing works
Cowart, K., Singleton, J., & Carris, N. W. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.06.011 · Cited by 11 · see citing works
Kayani, T., Ahmad, B., Chang, R., Qian, F., Sahinoz, M., Rehan, M., Giaimo, A., Spatz, E. S., & Hu, J. (2024) · Pharmacoepidemiology · doi:10.3390/pharma3010009 · Cited by 9 · see citing works
The role of atherogenic lipoproteins in diabetes: Molecular aspects and clinical significance
Banerjee, Y., Patti, A. M., Giglio, R. V., Ciaccio, M., Vichithran, S., Faisal, S., Stoian, A. P., Rizvi, A. A., & Rizzo, M. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108517 · Cited by 8 · see citing works
PCSK9 siRNA INHIBITOR INCLISIRAN AS A TREATMENT OPTION IN HYPERCHOLESTEROLEMIA: A BRIEF REVIEW
Kılıç, M. E. (2023) · TURKISH MEDICAL STUDENT JOURNAL · doi:10.4274/tmsj.galenos.2023.2023-5-1 · Cited by 3 · see citing works
Fadah, K., Alomari, M., Elchouemi, M., & Lange, R. A. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02362-8 · Cited by 1 · see citing works
Consideration for Health Disparities in Value Assessment Frameworks
Seo, D., Patil, D., Vandigo, J., & Mattingly, T. J. (2024) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s471855 · Cited by 1 · see citing works
Small Interfering RNA for LDL-Cholesterol Reduction
Batista, F., Mamede, I., & Dacoregio, M. (2026) · JACC: Advances · doi:10.1016/j.jacadv.2026.102932
Bempedoic Acid in Patients with Dyslipidemia: A Systematic Review and Meta-Analysis
Samajdar, S. S., Sarkar, S., Chakraborty, S., Sarkar, D., Ghosh, S., Banerjee, S., Biswas, K., Pal, J., Chatterjee, N., Bandyopadhyay, S. K., et al. (2025) · Medical Journal of Dr D Y Patil Vidyapeeth · doi:10.4103/mjdrdypu.mjdrdypu_576_24
- Authors
- Agboola, F., Lin, G. A., Kazi, D. S., McKenna, A., & Pearson, S. D.
- Affiliations
- Institute for Clinical and Economic Review (US)
- University of California, San Francisco (US)
- Beth Israel Deaconess Medical Center (US)
- Venue
- Journal of Managed Care & Specialty Pharmacy
- Publisher
- Academy of Managed Care Pharmacy
- Published
- 2021-07
- Volume
- 27
- Issue
- 7
- Pages
- 961-966
- ISSN
- 2376-0540 (ISSN-L)
- 2376-1032
- PMC
- PMC10391137
- OpenAlex
- W3176670679
- Cited by
- 12
- References
- 18
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 2 · 2023: 4 · 2022: 2 · 2021: 1
- FWCI
- 2.11
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Managed Care & Specialty Pharmacy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- bempedoic acid, inclisiran, heterozygous familial hypercholesterolemia, secondary prevention, atherosclerotic cardiovascular disease, PCSK9 inhibition, lipid-lowering therapy, cost-effectiveness
- MeSH terms
- Hypolipidemic Agents, Coronary Artery Disease, Cost-Benefit Analysis, Dicarboxylic Acids, Drug Therapy, Combination, Fatty Acids, Humans, Hypercholesterolemia, Treatment Outcome, Models, Economic, RNA, Small Interfering, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
